Oct 08,2019

Dexcom Announces FDA Clearance of New Dexcom G6 Pro CGM

Dexcom, Inc. announced today the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G6 Pro Continuous Glucose Monitoring (CGM) System for healthcare professionals to use with their patients, ages two years and up.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 08,2019

Walmart Brings One Drop’s Diabetes Management Platform to Hundreds of Retail Stores Nationwide

One Drop, a leader in digital therapeutics solutions for diabetes and other chronic conditions, today announced that its wireless glucose meter kit and supplies are now available at hundreds of Walmart stores in the United States. Each kit includes a Bluetooth glucose meter, lancing device, carry case, test strips and lancets, as well as one year of free access to One Drop’s certified diabetes coaches for 24/7 support.

COLLABORATION PARTNERSHIP

#institution

#bgm

View Analyst & Ambassador Comments
Go to original news
Oct 15,2019

Abbott and Tandem Diabetes Care Exploring New Integrated Solutions to Improve Diabetes Management

Abbott and Tandem Diabetes Care announced today that they intend to develop and commercialize integrated diabetes solutions that combine Abbott's world-leading glucose sensing technology with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes.

PRODUCT

#insulin pump

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Oct 16,2019

Tandem Diabetes Care Announces NEJM Publication of Landmark Study Demonstrating Increased Time-In-Range with the t:slim X2 Insulin Pump with Control-IQ Technology

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, today announced publication by the New England Journal of Medicine (NEJM) of results from the landmark Protocol 3 study (DCLP3) of the National Institutes of Health (NIH)-funded International Diabetes Closed Loop (iDCL) trial using the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed-loop technology.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Oct 24,2019

Senseonics Announces a Positive Coverage Decision for Eversense CGM From Humana

Senseonics Holdings, Inc. a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Humana is now providing coverage for the Eversense CGM System and insertion procedure, effective October 22, 2019. Under the Humana coverage policy patients with both type 1 diabetes and type 2 diabetes that require insulin are eligible for coverage for Eversense.

COLLABORATION PARTNERSHIP

#insurance

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 25,2019

Fiasp® Rapid Acting Insulin for Adults Now Approved for Use With the Omnipod Insulin Management System Platform in the United States

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced FDA clearance for use of Fiasp® (fast-acting insulin aspart) with the Omnipod® Insulin Management System and the Omnipod DASH™ Insulin Management System for adults.

REGULATORY FDA

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Oct 28,2019

Virta Health Partners with Accolade to Expand Access to Type 2 Diabetes Reversal Treatment

To truly change the course of the diabetes epidemic and reach our goal of reversing type 2 diabetes in 100 million people by 2025, we need help from partners who are as passionate as we are about bringing transformational healthcare solutions to patients. This is why we are so excited to announce that Virta is partnering with Accolade, a leading personalized advocacy and population health solution for employers and health plans.

COLLABORATION PARTNERSHIP

#institution

View Analyst & Ambassador Comments
Go to original news
Oct 30,2019

Tandem Diabetes Care Presents Positive Real-World Data from Pediatric Users of t:slim X2 Insulin Pump with Basal-IQ Technology at International Conference

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, today announced presentation of real-world data from pediatric users of the t:slim X2™ insulin pump with Basal-IQ® predictive low-glucose suspend technology at the 45th annual conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 05,2019

WellDoc's BlueStar cleared for Type 1 diabetes management, CGM integrations

This is the seventh FDA clearance for the longstanding mobile diabetes management platform.

REGULATORY FDA
View Analyst & Ambassador Comments
Go to original news
Nov 05,2019

Bayer Invests in UK Health Tech Firm Medopad

AI start-up Medopad, a crucial Health tech partner of Tencent has received $25m (£19.3m) as Series-B funding from German Pharmaceutical giant Bayer. Medopad's focus is on efforts to build digital biomarkers to diagnose diseases that are not detected easily by doctors or blood tests. The collected data from patients will be used by Medopad to analyze the progress of diseases. Alzheimer‘s and Diabetes are the other focus areas.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES